hotspot -WSS

hotspot

author：knowledge 2025-09-27 10:05:21 - browse：61

Illumina said Monday afternoon that its board of directors had approved a spin-off of its cancer test subsidiary Grail, signaling that a nearly four-year-long, $8 billion saga will finally draw to a close this month.

Shares in the newly independent Grail are expected to be distributed on June 24, Illumina said in a statement. Illumina will retain a 14.5% stake in the company, which will trade under the ticker $GRAL.

It’s the second time Illumina has spun off Grail, which initially began as a unit within the DNA sequencing giant in 2015. Illumina turned it into an independent company the following year but then agreed to reacquire it for $8 billion in September 2020.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Gut bacteria may contribute to kidney autoimmunity, study finds

WSS

Republican states more likely to report Covid vaccine side effects

Scientific mystery highlights the blind spots in genomics databases

People with mental disorders often marry others with same

Young boy dies in trial for Pfizer Duchenne gene therapy

Overprescribed: High cost isn't America's only drug problem

Scientists uncover potential path to treating deadly childhood tumor

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Alkermes shareholders re

Young boy dies in trial for Pfizer Duchenne gene therapy

Anesthesiologist group: stop taking Ozempic before surgery

Medicare Advantage 2025 payments will dip, Biden administration says

Moonlake's readout produced a cash windfall. Risks remain

U.K. decision on ALS drug has neurologists, advocates up in arms

DIEP, the 'gold standard' of breast reconstruction, is under threat

Bird flu reported in person exposed to presumably infected cattle

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

UnitedHealth, in a surprise, takes aim at Steward’s physician group

entertainment

Study: Black kids more likely to die after surgery than white kids

Pancreatic cancer is often deadly, but new discoveries are raising hope

Florida Supreme Court upholds state's abortion ban

Young boy dies in trial for Pfizer Duchenne gene therapy

Multiple sclerosis has subtypes with different best treatments: study

Covid silver lining: Unprecedented look at human immune system

entertainment

entertainment

Wikipedia

knowledge